GRN and posterior cortical atrophy: Considering that we have found, in a separate study [19], that serum GP88 levels were also associated with clinical outcomes, particularly in younger PCa patients, the combination of GP88 measurements in tumor biopsies and in serum would provide cost-effective assays to improve the management of PCa patients.